Glenmark life sciences share price

Post its strong March quarter results, BofA Securities recently upped its target price on the stock to Rs 630 from Rs 530 earlier, citing favourable risk-reward. BOB Capital Markets which finds Neuland Laboratories, Aarti Drugs and Solara Active Pharma as peers, suggested target of Rs 600 on the stock last month. The stock has breached that target on Monday. ET cited sources as saying that ChrysCapital is also said to be looking at the opportunity, but have yet to make any binding bids. Sekhmet is an active pharma ingredient (API) platform backed by private equity groups PAG, CX Partners and Samara Capital. Glenmark Life Sciences is also an API developer and manufacturer. ChrysCapital, another homegrown fund, is also evaluating the opportunity of teaming up with limited partners GIC of Singapore and Canada's CDPQ, several people aware of the matter told ET. However, the firm is yet to take a call on the matter and might opt out before binding bids are submitted by end of June, it suggested.

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. Its products focuses on chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes. The company was founded on June 23, 2011 and is headquartered in Mumbai, India. GLS took its time to give us a double bottom breakout and went on to hit 535 which was th target...on the way it broke the resistance at 480 levels with a breakaway gap, if you may, and thereafter consolidated upon hitting 535 being the double bottom target... few days back when it was trading at 52 GLS took its time to give us a double bottom breakout and went on to hit 535 which was th target...on the way it broke the resistance at 480 levels with a breakaway gap, if you may, and thereafter consolidated upon hitting 535 being the double bottom target... few days back when it was trading at 52 Stock Name - Glenmark Life Sciences Ltd Ichimoku Cloud Setup : 1). Today's close is above the Conversion Line 2). Future Kumo is Turning Bullish 3). Chikou span is slanting upwards All these parameters are showing bullishness at Current Market Price and more bullishness AFTER crossing 545 #Th Stock Name - Glenmark Life Sciences Ltd Ichimoku Cloud Setup : 1). Today's close is above the Conversion Line 2). Future Kumo is Turning Bullish 3). Chikou span is slanting upwards All these parameters are showing bullishness at Current Market Pri...

Date Open High Low Close Volume 15/06/2023 611.70 611.70 601.00 601.70 89722 14/06/2023 607.00 614.35 602.80 609.70 86538 13/06/2023 615.00 617.55 602.75 607.35 177495 12/06/2023 600.00 619.65 600.00 611.20 398423 09/06/2023 580.95 595.15 576.95 590.45 190749 08/06/2023 582.00 584.00 572.15 575.90 160153 07/06/2023 545.10 584.00 545.10 581.05 731079 06/06/2023 540.00 550.00 534.05 548.45 135507 05/06/2023 551.00 551.80 533.00 537.10 141318 02/06/2023 548.00 554.80 542.15 547.85 142800 01/06/2023 538.00 547.15 536.05 542.90 109192 31/05/2023 533.10 547.50 531.30 540.50 89834 30/05/2023 543.50 549.75 534.50 536.95 95587 29/05/2023 558.10 559.00 542.05 544.30 262839 26/05/2023 536.25 560.10 535.00 552.95 421778 25/05/2023 540.00 553.50 528.70 533.25 251890 24/05/2023 523.00 540.00 516.15 538.25 287438 23/05/2023 529.30 539.00 515.10 519.10 249091 22/05/2023 525.00 534.55 513.10 528.70 167349 19/05/2023 533.95 533.95 521.40 526.40 201212 18/05/2023 534.00 539.85 521.00 524.80 319408 17/05/2023 520.65 538.95 518.00 528.80 195787

• Adani Enterp. 2457.30 ↑ 6.15 (0.25%) • Adani Ports 743.45 ↑ 8.50 (1.16%) • Apollo Hospitals 4944.90 ↑ 18.20 (0.37%) • Asian Paints 3175.20 ↓ -5.35 (-0.17%) • Axis Bank 975.20 ↑ 0.45 (0.05%) • B P C L 367.20 ↑ 7.75 (2.16%) • Bajaj Auto 4758.50 ↑ 15.10 (0.32%) • Bajaj Finance 7099.00 ↑ 61.85 (0.88%) • Bajaj Finserv 1464.30 ↓ -2.20 (-0.15%) • Bharti Airtel 835.05 ↑ 1.55 (0.19%) • Britannia Inds. 4895.00 ↑ 16.25 (0.33%) • Cipla 968.00 ↓ -1.25 (-0.13%) • Coal India 228.45 ↑ 0.80 (0.35%) • Divi's Lab. 3450.00 ↑ 21.25 (0.62%) • Dr Reddy's Labs 4690.55 ↑ 23.75 (0.51%) • Eicher Motors 3592.00 ↑ 10.70 (0.30%) • Grasim Inds 1720.20 ↑ 4.45 (0.26%) • H D F C 2641.60 ↓ -11.30 (-0.43%) • HCL Technologies 1135.65 ↑ 25.90 (2.33%) • HDFC Bank 1602.50 ↓ -8.10 (-0.50%) • HDFC Life Insur. 585.45 ↑ 3.75 (0.64%) • Hero Motocorp 2919.90 ↑ 20.60 (0.71%) • Hind. Unilever 2646.05 ↑ 9.85 (0.37%) • Hindalco Inds. 418.00 ↑ 2.95 (0.71%) • ICICI Bank 938.45 ↑ 0.40 (0.04%) • IndusInd Bank 1326.60 ↓ -4.45 (-0.33%) • Infosys 1291.45 ↑ 25.50 (2.01%) • ITC 434.55 ↓ -3.90 (-0.89%) • JSW Steel 748.90 ↑ 0.40 (0.05%) • Kotak Mah. Bank 1877.85 ↑ 5.85 (0.31%) • Larsen & Toubro 2339.70 ↓ -23.30 (-0.99%) • M & M 1376.50 ↑ 5.85 (0.43%) • Maruti Suzuki 9550.00 ↓ -77.80 (-0.81%) • Nestle India 22222.85 ↑ 149.40 (0.68%) • NTPC 185.60 ↑ 2.80 (1.53%) • O N G C 155.00 ↑ 0.75 (0.49%) • Power Grid Corpn 242.60 ↓ -2.30 (-0.94%) • Reliance Industr 2478.95 ↓ -3.00 (-0.12%) • SBI Life Insuran 1248.30 ↑ 15.90 (1.29%) • St Bk of ...

Als u op ' Alles accepteren' klikt, gebruiken wij en • gepersonaliseerde advertenties en content weergeven op basis van interesseprofielen • de effectiviteit meten van gepersonaliseerde advertenties en content, en • onze producten en services ontwikkelen en verbeteren Als u niet wilt dat wij en onze partners cookies en persoonsgegevens voor deze aanvullende doeleinden gebruiken, klik dan op ' Alles weigeren'. Als u uw keuzes wilt aanpassen, klik dan op ' Privacyinstellingen beheren'. Je kunt je keuzes te allen tijde wijzigen door te klikken op de links 'Privacy- en cookie-instellingen' of 'Privacydashboard' op onze sites en in onze apps. Lees ons

Return on average equity - 5 year average - Net Income/employee - trailing 12 month - Revenue/employee - most recent fiscal year - Return on investment - most recent fiscal year 21.80 Return on average assets - most recent fiscal year 18.05 Receivables turnover - most recent fiscal year 2.92 Return on investment - trailing 12 month 21.80 Return on average assets - trailing 12 month 18.05 Inventory turnover - most recent fiscal year 1.81 Inventory turnover - trailing 12 month 1.81 Revenue/employee - trailing 12 month - Return on average assets - 5 year average - Net Income/employee - most recent fiscal year - Return on average equity - trailing 12 month 22.28 Receivables turnover - trailing 12 month 2.92 Asset turnover - most recent fiscal year 0.84 Asset turnover - trailing 12 month 0.84 Return on average equity - most recent fiscal year 22.28 Return on investment - 5 year average -

Period Mar 2023 Mar 2022 Mar 2021 Mar 2020 Total Revenue 2161.22 2123.21 1885.17 1537.31 Selling/ General/ Admin Expenses Total 180.18 463.52 384.55 373.67 Depreciation/ Amortization 42.09 37.88 33.39 29.37 Other Operating Expenses Total 295.70 -0.32 -0.38 -0.40 Total Operating Expense 1532.06 1543.97 1323.06 1093.10 Operating Income 629.16 579.25 562.10 444.22 Net Income Before Taxes 628.61 564.92 470.94 421.07 Net Income 466.96 418.72 351.58 313.10 Diluted Normalized EPS 38.11 35.67 28.73 25.63 ABOUT Glenmark Life Sciences • Industry Biotechnology & Drugs • ISIN INE03Q201024 • BSE Code 543322 • NSE Code GLS Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mah...

Glenmark Life Sciences Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Glenmark Life Sciences Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/284558/glenmark-life-sciences-ltd/ Get Glenmark Life Sciences Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management. It also provides Atovaquone, Remogliflozin, Teneligliptin, Zonisamide, and Adapalene. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.

Post its strong March quarter results, BofA Securities recently upped its target price on the stock to Rs 630 from Rs 530 earlier, citing favourable risk-reward. BOB Capital Markets which finds Neuland Laboratories, Aarti Drugs and Solara Active Pharma as peers, suggested target of Rs 600 on the stock last month. The stock has breached that target on Monday. ET cited sources as saying that ChrysCapital is also said to be looking at the opportunity, but have yet to make any binding bids. Sekhmet is an active pharma ingredient (API) platform backed by private equity groups PAG, CX Partners and Samara Capital. Glenmark Life Sciences is also an API developer and manufacturer. ChrysCapital, another homegrown fund, is also evaluating the opportunity of teaming up with limited partners GIC of Singapore and Canada's CDPQ, several people aware of the matter told ET. However, the firm is yet to take a call on the matter and might opt out before binding bids are submitted by end of June, it suggested.

Date Open High Low Close* Adj Close** Volume Jun 16, 2023 601.70 616.00 586.50 601.50 601.50 239,425 Jun 15, 2023 611.70 611.70 601.00 601.70 601.70 89,722 Jun 14, 2023 607.00 614.35 602.80 609.70 609.70 86,538 Jun 13, 2023 615.00 617.55 602.75 607.35 607.35 177,495 Jun 12, 2023 600.00 619.65 600.00 611.20 611.20 398,423 Jun 09, 2023 580.95 595.15 576.95 590.45 590.45 190,749 Jun 08, 2023 582.00 584.00 572.15 575.90 575.90 160,153 Jun 07, 2023 545.10 584.00 545.10 581.05 581.05 731,079 Jun 06, 2023 540.00 550.00 534.05 548.45 548.45 135,507 Jun 05, 2023 551.00 551.80 533.00 537.10 537.10 141,318 Jun 02, 2023 548.00 554.80 542.15 547.85 547.85 142,800 Jun 01, 2023 538.00 547.15 536.05 542.90 542.90 109,192 May 31, 2023 533.10 547.50 531.30 540.50 540.50 89,834 May 30, 2023 543.50 549.75 534.50 536.95 536.95 95,587 May 29, 2023 558.10 559.00 542.05 544.30 544.30 262,839 May 26, 2023 536.25 560.10 535.00 552.95 552.95 421,778 May 25, 2023 540.00 553.50 528.70 533.25 533.25 251,890 May 24, 2023 523.00 540.00 516.15 538.25 538.25 287,438 May 23, 2023 529.30 539.00 515.10 519.10 519.10 249,091 May 22, 2023 525.00 534.55 513.10 528.70 528.70 167,349 May 19, 2023 533.95 533.95 521.40 526.40 526.40 201,212 May 18, 2023 534.00 539.85 521.00 524.80 524.80 319,408 May 17, 2023 520.65 538.95 518.00 528.80 528.80 195,787 May 16, 2023 535.00 539.45 519.95 523.95 523.95 170,952 May 15, 2023 536.25 544.85 521.60 527.40 527.40 209,778 May 12, 2023 538.05 544.75 532.55 536.25 536.25 378,896 ...